This post was originally published on this site
Furthermore, MRK announced recently that its experimental COVID-19 antiviral treatment, molnupiravir, could get U.S. emergency use authorization before the year-end. The company also said that the COVID-19 pandemic would have a negligible impact on its operating expenses.
MRK expects sales growth to be between 12% to 14% in its fiscal year 2021. The company’s revenue is estimated to be between $46.40 billion and $47.40 billion, and its non-GAAP EPS is expected to be between $5.47 and $5.57 in the current year. So, the stock’s near-term prospects look promising.
